15-PGDH in colon cancer

摘要

The disclosure provides, among other things, a method of decreasing resistance to the chemopreventive properties of non-steroidal anti-inflammatory agents, e.g., celecoxib, particularly in the prevention of cancer, e.g., colon cancer, by increasing the levels or activity of 15-hydroxyprostaglandin dehydrogenase (15-PGDH). The disclosure also provides a method of identifying compounds that upregulate or reactivate 15-PGDH. The disclosure also provides a method of identifying an individual suitable for treatment with a non-steroidal anti-inflammatory agent in the treatment or prevention of colon cancer.

主权项

1. A method of treating a non-steroidal anti-inflammatory drug (NSAID)-responsive condition in a human subject, wherein the NSAID-responsive condition is selected from the group consisting of: an inflammatory disorder, an immunologic disorder, and colon neoplasia, and wherein the subject has been determined to have increased or decreased levels of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), the method comprising:
(i) administering to the subject an effective amount of an NSAID if the levels of 15-PGDH are increased; or (ii) administering to the subject an effective amount of an NSAID and an agent that upregulates 15-PGDH, wherein the agent is not a Prox-1 suppressor, if the levels of 15-PGDH are decreased.